“. Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts throughout 2018+.”,” the firm’s analyst wrote.
A number of other equities research analysts have also recently weighed in on the company. Oppenheimer set a $30.00 price target on Spero Therapeutics and gave the company a buy rating in a report on Monday, July 16th. HC Wainwright began coverage on Spero Therapeutics in a report on Friday, May 11th. They set a buy rating and a $28.00 price target on the stock. Finally, ValuEngine raised Spero Therapeutics from a sell rating to a hold rating in a report on Wednesday, May 2nd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Spero Therapeutics presently has a consensus rating of Buy and a consensus price target of $25.00.
Shares of SPRO traded down $0.03 during mid-day trading on Thursday, reaching $11.27. 68,672 shares of the company’s stock traded hands, compared to its average volume of 230,178. Spero Therapeutics has a 12 month low of $9.66 and a 12 month high of $19.00.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Thursday, August 9th. The company reported ($0.69) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.77) by $0.08. The company had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.62 million. Spero Therapeutics had a negative return on equity of 182.49% and a negative net margin of 1,479.91%. analysts anticipate that Spero Therapeutics will post -3.2 earnings per share for the current year.
In related news, insider Ankit Mahadevia sold 4,676 shares of the firm’s stock in a transaction that occurred on Friday, July 6th. The shares were sold at an average price of $17.63, for a total transaction of $82,437.88. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Plc Glaxosmithkline acquired 80,000 shares of the stock in a transaction that occurred on Tuesday, July 17th. The shares were bought at an average price of $12.50 per share, for a total transaction of $1,000,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 10,676 shares of company stock worth $187,438. Corporate insiders own 26.90% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BVF Inc. IL increased its stake in shares of Spero Therapeutics by 1.9% during the first quarter. BVF Inc. IL now owns 1,048,958 shares of the company’s stock valued at $14,948,000 after acquiring an additional 19,773 shares during the period. BlackRock Inc. increased its stake in shares of Spero Therapeutics by 35.6% during the second quarter. BlackRock Inc. now owns 341,999 shares of the company’s stock valued at $5,017,000 after acquiring an additional 89,698 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Spero Therapeutics by 19,604.3% during the first quarter. JPMorgan Chase & Co. now owns 256,353 shares of the company’s stock valued at $3,653,000 after acquiring an additional 255,052 shares during the period. DAFNA Capital Management LLC increased its stake in shares of Spero Therapeutics by 490.9% during the first quarter. DAFNA Capital Management LLC now owns 29,544 shares of the company’s stock valued at $421,000 after acquiring an additional 24,544 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Spero Therapeutics by 73.9% during the second quarter. Bank of New York Mellon Corp now owns 24,689 shares of the company’s stock valued at $363,000 after acquiring an additional 10,490 shares during the period. Institutional investors and hedge funds own 45.92% of the company’s stock.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Featured Article: NASDAQ
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.